X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
IMB-150 (also known as LYT-503) as a potential non-opioid treatment for female patients with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). IMB-150, is a novel formulation of lidocaine, and the clinical development program is called GainMe-IC.
Lead Product(s): IMB-150
Therapeutic Area: Urology Product Name: LYT-503
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2022
Details:
Under the terms of the agreement, Imbrium is responsible for all future development activities and funding for LYT-503/IMB-150, for which an IND filing is planned for early 2022.
Lead Product(s): IMB-150
Therapeutic Area: Urology Product Name: LYT-503
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: PureTech Health
Deal Size: $59.5 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 11, 2021
Details:
IMB-115 is a novel, highly potent and selective partial agonist for nociceptin/orphanin-FQ peptide (NOP) receptors designed to promote sleep onset and maintenance at doses that show minimal or no residual next-day somnolence (drowsiness) or psychomotor impairment.
Lead Product(s): IMB-115
Therapeutic Area: Sleep Product Name: IMB-115
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 28, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
